Charles River Laboratories International, Inc. (CRL)
Stock Price:
$222.00 USD
-7.26 (-3.17%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
11.03B |
| Revenue (ttm) |
2.75B |
| Net Income (ttm) |
271.36M |
| Shares Out |
49.68M |
| EPS (ttm) |
5.44 |
| PE Ratio |
40.81 |
| Forward PE |
28.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$222.00 |
| Previous Close |
$229.26 |
| Change ($) |
-7.26 |
| Change (%) |
-3.17% |
| Day's Open |
225.00 |
| Day's Range |
221.90 - 225.25 |
| Day's Volume |
338,400 |
| 52-Week Range |
95.58 - 250.29 |
More Stats
| Market Cap |
11.03B |
| Enterprise Value |
13.03B |
| Earnings Date (est) |
Oct 29, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.68M |
| Float |
48.88M |
| EPS (basic) |
5.52 |
| EPS (diluted) |
5.44 |
| FCF / Share |
8.39 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
2.45% |
| FCF Yield |
3.77% |
| Payout Ratio |
n/a |
| Shares Short |
632,579 |
| Short Ratio |
1.98 |
| Short % of Float |
1.29% |
| Beta |
1.13 |
| PE Ratio |
40.81 |
| Forward PE |
28.25 |
| P/FCF Ratio |
26.52 |
| PS Ratio |
4.01 |
| PB Ratio |
6.63 |
| Revenue |
2.75B |
| Operating Income |
372.64M |
| Net Income |
271.36M |
| Free Cash Flow |
415.90M |
| Net Cash |
-2.01B |
| Net Cash / Share |
-40.38 |
| Gross Margin |
35.11% |
| Operating Margin |
13.56% |
| Profit Margin |
9.90% |
| FCF Margin |
15.13% |
| ROA |
4.98% |
| ROE |
16.73% |
| ROIC |
10.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (19)
| Buy |
15 |
| Overweight |
1 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$245.69*
(10.67% upside)
Low
203
Current: $222.00
High
281
Target: 245.69
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2,621 | 2,266 | 1,858 | 1,681 | 1,363 | 1,298 | 1,166 | 1,130 | 1,143 | 1,133 |
| Revenue Growth | 15.67% | 21.99% | 10.48% | 23.34% | 5.06% | 11.34% | 3.19% | -1.15% | 0.81% | - |
| Gross Profit | 958 | 840 | 701 | 644 | 531 | 473 | 395 | 392 | 402 | 385 |
| Operating Income | 351 | 331 | 288 | 238 | 206 | 178 | 151 | 166 | 174 | -299 |
| Net Income | 252 | 226 | 123 | 155 | 149 | 127 | 103 | 97.30 | 110 | -337 |
| Shares Outstanding | 48.73 | 47.95 | 47.48 | 47.01 | 46.62 | 46.92 | 48.12 | 48.55 | 49.44 | 57.72 |
| Earnings Per Share | 5.07 | 4.62 | 2.54 | 3.23 | 3.13 | 2.66 | 2.12 | 2.01 | 2.14 | -5.38 |
| EPS Growth | 9.74% | 81.89% | -21.36% | 3.19% | 17.67% | 25.47% | 5.47% | -6.07% | - | - |
| Operating Cash Flow | 481 | 441 | 318 | 317 | 307 | 252 | 209 | 208 | 207 | 168 |
| Capital Expenditures | -141 | -140 | -82.43 | -55.29 | -63.25 | -56.93 | -39.15 | -47.53 | -49.14 | -42.86 |
| Free Cash Flow | 340 | 301 | 236 | 262 | 244 | 195 | 170 | 160 | 158 | 125 |
| Cash & Equivalents | 238 | 195 | 164 | 118 | 118 | 160 | 156 | 110 | 68.91 | 179 |
| Total Debt | 2,004 | 1,668 | 1,145 | 1,235 | 863 | 772 | 664 | 667 | 718 | 701 |
| Net Cash / Debt | -1,766 | -1,473 | -981 | -1,117 | -745 | -612 | -508 | -557 | -649 | -522 |
| Assets | 4,693 | 3,856 | 2,930 | 2,712 | 2,068 | 1,871 | 1,633 | 1,586 | 1,558 | 1,733 |
| Liabilities | 3,026 | 2,518 | 1,866 | 1,858 | 1,303 | 1,166 | 968 | 983 | 1,031 | 1,045 |
| Book Value | 1,635 | 1,317 | 1,045 | 837 | 733 | 672 | 641 | 601 | 526 | 687 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Charles River Laboratories International, Inc. |
| Country |
United States |
| Employees |
17,100 |
| CEO |
James C. Foster |
Stock Information
| Ticker Symbol |
CRL |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NYSE: CRL |
| IPO Date |
June 23, 2000 |
Description
Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.